About Sherri-Ann Burnett-Bowie, MD, MPH

Sherri-Ann M. Burnett-Bowie MD, MPH is an Associate Professor of Medicine at Harvard Medical School and a clinical investigator in the Massachusetts General Hospital Endocrine Unit, where her research focuses on the epidemiology of menopause and clinical trials of treatments for osteoporosis. She cares for patients seen at the Mass General Endocrine Associates and the Mass General Bone Density Center. Dr. Burnett-Bowie is Associate Director of the Mass General Center for Diversity and Inclusion and the Chair of the Diversity and Inclusion Board in the Department of Medicine. Teaching and increasing diversity and inclusion are central to her mission.

Departments, Centers, & Programs:

Clinical Interests:



Mass General Endocrinology: Thyroid Associates
55 Fruit St.
Wang Ambulatory Care Center
Suite 730
Boston, MA 02114
Phone: 617-726-8720

Medical Education

  • MPH, Harvard T. H Chan School of Public Health
  • MD, University of Pittsburgh School of Medicine
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Endocrinology, Diabetes and Metabolism, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Burnett-Bowie's  research is focused on skeletal and non-skeletal consequences of vitamin D deficiency, and clinical trials of treatments for osteoporosis.


  • Select Publications:

    • Burnett, SM, S Gunawardene, FR Bringhurst et al.  Regulation of c-terminal and intact FGF23 by dietary phosphate in men and women.  JBMR 2006.
    • Burnett-Bowie, SM , BZ Leder, MP Henao et al. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. CJASN 2012.
    • Mitchell, DM, MP Henao, JS Finkelstein, SM Burnett-Bowie. Prevalence & predictors of vitamin D deficiency in healthy adults. JCEM 2012.
    • Tsai, JN, Uihlein, AV, H Lee et al. Teriparatide & denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013
    • Finkelstein , JS, H. Lee, SM Burnett-Bowie et al. Gonadal steroids & body composition, strength, and sexual function in men. NEJM 2013

Reviews: Comments and Ratings